Please assess the completion status of the following clinical trial:

Trial Title: Effect and Safety Study of Atorvastatin to Treat Chronic Subdural Hematoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 and \<90 years old, male or female;~2. CT scan reveals supratentorial, unilateral or bilateral chronic subdural hematoma (MRI scan is warranted if diagnosis is difficult);~3. Markwalder's Grading Scale and Glasgow Coma Scale (MGS-GCS)\<Grade 3;~4. Attending physician makes a judgment that cerebral hernia would not occur and surgical operation might not be performed in a short time. Conservative treatment is adopted;~5. Patients have never undergo surgery on the hematoma~6. Patient fully understood the nature of the study, and voluntarily participates and signs informed consent.~Exclusion Criteria:~1. Allergic to the statin or its ingredients~2. Cerebral herniation might occur at any time;~3. Hematoma leads to herniation and warrants surgical operation.~4. Hematoma caused by tumors, blood and other known comorbidities;~5. Abnormal liver function~6. Uncontrolled hepatitis and other liver diseases, as well as suffering from other disease may interfere the study~7. Patients have been on oral Statin treatment for a long time.~8. Patients have been on oral Steroids treatment for a long time.~9. Participate in clinical trials in the past four weeks;~10. Pregnant or breastfeeding~11. Failure of completing the trial by poor compliance;~12. For any reason, the researchers believe that the case is not suitable for inclusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: EXPERIMENTAL): atorvastatin：20 mg (every evening orally) for 8 weeks
- placebo (Type: PLACEBO_COMPARATOR): placebo:20 mg (every evening orally) for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).